Medeon Biodesign, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 05, 2021
Share
Medeon Biodesign, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was TWD 38.386 million compared to TWD 14.168 million a year ago. Operating loss was TWD 105.172 million compared to TWD 96.188 million a year ago. Net income was TWD 2,436.475 million compared to net loss of TWD 62.031 million a year ago. Basic earnings per share was TWD 36.83 compared to basic loss per share of TWD 0.94 a year ago. Basic loss per share from continuing operations was TWD 1.96 compared to TWD 1.27 a year ago. For the half year, sales was TWD 49.259 million compared to TWD 31.592 million a year ago. Operating loss was TWD 216.960 million compared to TWD 190.981 million a year ago. Net income was TWD 2,363.885 million compared to net loss of TWD 115.533 million a year ago. Basic earnings per share was TWD 35.73 compared to basic loss per share of TWD 1.74 a year ago. Basic loss per share from continuing operations was TWD 3.39 compared to TWD 2.47 a year ago.
Medeon Biodesign, Inc. is a Taiwan-based company principally engaged in the research, development, manufacture and sales of medical equipment. The Company's main products include medical apparatus and instruments used in laparoscopic minimally invasive surgeries and cardiac catheter-related minimally invasive surgeries. The Company distributes its products in domestic market and to overseas markets.
MEDEON BIODESIGN, INC. 
